SELLAS Life Sciences (SLS) Current Assets (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Current Assets data on file, last reported at $111.2 million in Q1 2026.

• Current Assets for Q1 2026 came in at $111.2 million, up 247.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.2 million (up 247.7% YoY), and the FY2025 annual result was $75.2 million, up 360.65% from the prior year.
• Current Assets grew to $111.2 million in Q1 2026 per SLS's latest filing, from $75.2 million in the prior quarter.
• Over five years, Current Assets peaked at $111.2 million in Q1 2026 and troughed at $3.2 million in Q4 2023.
• A 5-year average of $29.9 million and a median of $22.6 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 82.14% in 2023, then soared 414.72% in 2024.
• A 5-year view of Current Assets shows it stood at $17.8 million in 2022, then tumbled by 82.14% to $3.2 million in 2023, then soared by 414.72% to $16.3 million in 2024, then soared by 360.65% to $75.2 million in 2025, then soared by 47.81% to $111.2 million in 2026.
• Business Quant data shows SLS's Current Assets at $111.2 million in Q1 2026, $75.2 million in Q4 2025, and $49.1 million in Q3 2025.